Skip to main content

Table 1 Baseline Characteristics of patients with advanced NSCLC

From: Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

 

2009 (n = 580)

2011 (n = 778)

2015 (n = 1001)

2017 (n = 966)

 

Age <70

(n = 311)

Age ≥70

(n = 269)

p-value

Age <70

(n = 417)

Age ≥70

(n = 361)

p-value

Age <70

(n = 485)

Age ≥70

(n = 516)

p-value

Age <70

(n = 478)

Age ≥70

(n = 488)

p-value

Median Age at diagnosis (IQR)

61 (55–65)

76 (73–81)

< 0.001

62 (56–66)

76 (73–81)

< 0.001

61 (57–66)

77 (73–82)

< 0.001

62 (57–65)

78 (73–83)

< 0.001

Sex

Female

Male

147 (47%)

164 (53%)

130 (48%)

139 (52%)

0.803

208 (50%)

209 (50%)

173 (48%)

188 (52%)

0.615

262 (54%)

223 (46%)

258 (50%)

258 (50%)

0.206

249 (52%)

229 (48%)

225 (46%)

263 (54%)

0.071

Histology

Non-squamous

Squamous

NOS

129 (42%)

33 (11%)

149 (48%)

94 (35%)

52 (19%)

123 (46%)

0.010

280 (67%)

58 (14%)

79 (19%)

215 (59%)

64 (18%)

82 (23%)

0.087

328 (68%)

71 (14%)

86 (18%)

308 (60%)

83 (16%)

125 (24%)

0.020

312 (65%)

58 (12%)

108 (23%)

307 (63%)

61 (12%)

120 (25%)

0.725

EGFR Status

Positive

3 (< 1%)

0

 

32 (8%)

22 (6%)

0.387

50 (10%)

40 (8%)

0.157

72 (15%)

49 (10%)

0.018

ALK Status

Positive

0

0

 

1 (< 1%)

0

 

15 (3%)

3 (< 1%)

0.003

15 (3%)

1 (< 1%)

< 0.001

ECOG

0–1

≥2

Unknown

116 (37%)

171 (55%)

24 (8%)

78 (29%)

166 (62%)

25 (9%)

0.104

178 (43%)

176 (42%)

63 (15%)

105 (29%)

203 (56%)

53 (15%)

< 0.001

182 (37%)

240 (50%)

63 (13%)

133 (26%)

316 (61%)

67 (13%)

< 0.001

169 (35%)

258 (54%)

51 (11%)

118 (24%)

313 (64%)

57 (12%)

0.001

SCS

<9

≥9

240 (77%)

71 (23%)

115 (43%)

154 (57%)

< 0.001

295 (71%)

122 (29%)

167 (46%)

194 (54%)

0.001

333 (69%)

151 (31%)

207 (40%)

309 (60%)

< 0.001

330 (69%)

148 (31%)

195 (40%)

293 (60%)

< 0.001

Smoking

Never

Ever

Unknown

41 (13%)

268 (86%)

2 (1%)

27 (10%)

240 (89%)

2 (1%)

0.499

57 (13%)

358 (86%)

2 (1%)

48 (13%)

298 (83%)

15 (4%)

0.002

81 (17%)

391 (80%)

13 (3%)

88 (17%)

408 (79%)

20 (4%)

0.555

83 (17%)

389 (82%)

6 (1%)

69 (14%)

404 (83%)

15 (3%)

0.070

Lines of therapy

Best Supportive Care

1

2

≥3

173 (56%)

58 (18%)

43 (14%)

37 (12%)

208 (77%)

29 (11%)

16 (6%)

16 (6%)

< 0.001

196 (47%)

78 (19%)

73 (17%)

70 (17%)

271 (75%)

44 (12%)

30 (8%)

16 (5%)

< 0.001

240 (50%)

150 (31%)

56 (11%)

39 (8%)

372 (72%)

98 (19%)

29 (5%)

19 (4%)

< 0.001

229 (48%)

118 (25%)

81 (17%)

50 (10%)

342 (70%)

91 (19%)

38 (8%)

17 (3%)

< 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us